Polyclonal Anti-

8-Hydroxyguanosine Antiserum

8-Hydroxydeoxyguanosine (8OHdG) is a modified base that occurs in DNA due to attack by hydroxyl radicals that are formed as byproducts and intermediates of aerobic metabolism and during oxidative stress. There is increasing evidence to support the involvement of free radical reactions in the damage of biomolecules that eventually leads to several diseases in humans, such as arteriosclerosis, cerebral and heart ischemia-reperfusion injury, cancer, rheumatoid arthritis, inflammation, diabetes, aging, and neurodegenerative conditions, such as Alzheimer’s disease.

8OHdG has become increasing popular as a sensitive, stable and integral marker of oxidative damage in cellular DNA.  Biomonitoring in humans has demonstrated that 8OHdG can be excreted in the urine, and that a significant increase is caused by exposure to tobacco smoke and ionizing radiation.  Because 8OHdG is so well correlated with oxidative stress and damage to DNA, which leads to degenerative disease states, the development of an antibody that can be used to study DNA damage has numerous applications.  In addition to the direct study of DNA damage within cells, this antibody has applications in the development of immunoassays that can monitor 8OHdG excretion in the urine and serve as a biomarker of oxidative stress.  Industrial uses may extend to the dietary supplement manufacturers, who could benefit from an immunoassay that could be used to test the effectiveness of antioxidants and other nutraceuticals.

A goat antiserum to 8-hydroxyguanosine is currently available.  This antiserum has been shown by ELISA to be completely cross-reactive with 8-hydroxydeoxyguanosine while not cross-reacting with other naturally occurring nucleotides.  This antibody has also been shown to immunolabel Alzheimer disease neurons using formalin-fixed, paraffin-embedded tissue sections.  This antibody should be a valuable tool for scientists working to understand the role of free radical damage in a number of human disease states. 

This antiserum was produced using proprietary methodology whereby the haptin is attached to a carrier that elicits minimal immunoreactivity so that the antiserum has a higher degree of specificity for the haptin.  Since there is no overwhelming production of interfering antibodies to the carrier, this antiserum can routinely be used without further purification.  Pseud-Immune™ Control Immune Serum (Cat no. GPA018E) from a mock immunized animal is available to be used in conjunction with this antibody.

Manufacturing Reference:

Yin, B., et al. Free Radic. Biol. Med. 18: 1023-1032, 1995.